
Monoclonal Antibody Administration

Purpose: To allow for EMS to administer monoclonal antibodies with an order from a physician in multiple settings. This includes congregate care facilities and private residences.

- I. Verify that the patient meets screening criteria
 - A. Must be all of the following
 - i. ≥ 12 years old
 - ii. \geq least 40 kilograms
 - iii. Having mild to moderate COVID-19; high risk for progressing to severe COVID-19 and/or hospitalization
 - B. Must be at least one of the following
 - i. Has a body mass index (BMI) ≥ 35
 - ii. Has chronic kidney disease
 - iii. Has diabetes
 - iv. Has immunosuppressive disease
 - v. Is currently receiving immunosuppressive treatment
 - vi. Is ≥ 65 years of age
 - vii. Is ≥ 55 years of age AND has: cardiovascular disease or hypertension, or chronic obstructive pulmonary disease/other chronic respiratory disease.
 - C. Must not be
 - i. hospitalized due to COVID-19, OR
 - ii. requiring oxygen therapy due to COVID-19, OR
 - iii. requiring an increase in baseline oxygen flowrate due to COVID-19 for those on chronic oxygen therapy due to an underlying non-COVID-19 related co-morbidity.
- II. Bamlanivimab Injection
 - A. Verify patient has received (or give to patient) patient fact sheet
 - B. Inspect the medication. Bamlanivimab is a clear to opalescent and colorless to slightly yellow to slightly brown solution.
 - C. Bamlanivimab is supplied in a single dose vial of 700mg/20 mL
 - D. Dilute bamlanivimab using a 250 mL prefilled 0.9% Sodium Chloride Injection bag for intravenous infusion.
 - i. Withdraw 20 mL (700 mg) of bamlanivimab from the vial using an appropriately sized syringe.
 - ii. Transfer bamlanivimab to the 0.9% Sodium Chloride Injection infusion bag.
 - iii. Discard any product remaining in the vial.
 - E. Gently invert IV bag by hand approximately 10 times to mix. Do not shake.
 - F. Administer the infusion over at least 60 minutes.



Michigan
***EMERGENCY* COVID-19 PANDEMIC**
MONOCLONAL ANTIBODY ADMINISTRATION

Initial Date: 12/11/2020

Revised Date:

Section 14-13

Infusion Rates	
Drip Set	Maximum Drip Rate
10 gtt/mL	41 gtt/min
15 gtt/mL	62 gtt/min
60 gtt/mL	250 gtt/min

- G. Discontinue the infusion, keeping the IV in place during monitoring period.
 - H. Monitor the patient for any adverse reactions for at least 60 minutes after discontinuing the infusion.
- III. Documentation
- A. Notify prescribing provider of the completion of the infusion and/or the
 - B. Any medication errors or serious adverse events must be reported by the prescribing health care provider.
 - C. Electronic Patient Care Reports must be generated for any administration inside private residences.

MCA Name:

MCA Board Approval Date:

MCA Implementation Date:

Protocol Source/References: <https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab/Documents/Bamlanivimab-Pocket-Resource-Card.pdf>,
<https://www.covid19.lilly.com/assets/pdf/bamlanivimab/lilly-antibodies-playbook.pdf>